<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555685</url>
  </required_header>
  <id_info>
    <org_study_id>FAPESP 2007/04048-7</org_study_id>
    <nct_id>NCT00555685</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline Solution in Heart Failure</brief_title>
  <official_title>Hypertonic Saline Solution in Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with decompensated heart failure have high rates of mortality and morbidity despite
      recent improvements in diagnosis and treatment. Some aspects of their presentation such as
      renal failure, hyponatremia and congestive phenomena have received special attention, as they
      are associated with worse prognosis. The infusion of hypertonic saline solution has been
      tested in different conditions of cardiovascular collapse. Current evidence indicates that
      the infusion of hypertonic solution in heart failure patients can provide clinical and
      haemodynamic improvement. The investigators are testing the hypothesis that the infusion of
      hypertonic solution in association with diuretics may prevent the occurrence of renal
      dysfunction in patients with decompensated heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of renal disfunction</measure>
    <time_frame>During hospital admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of hyponatremia</measure>
    <time_frame>During hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of congestive phenomena</measure>
    <time_frame>During hospital admission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Heart Failure</condition>
  <condition>Renal Failure</condition>
  <condition>Hyponatremia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group of patients that will receive hypertonic saline solution (NaCl 7,5%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group of patients that will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 7,5% (Hypertonic Saline Solution)</intervention_name>
    <description>Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 0,9%</intervention_name>
    <description>Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years old

          -  Heart failure according to Framingham criteria

          -  Episode of acute decompensation,with need of in-hospital treatment

          -  Presence of congestive phenomena

        Exclusion Criteria:

          -  Patient denial

          -  Left-ventricle ejection fraction over 0,4, as measure by transthoracic
             echocardiography

          -  Rheumatic disease

          -  Restrictive cardiomyopathy

          -  Alcohol abuse

          -  Chronic obstructive pulmonary disease

          -  Cancer

          -  Pulmonary embolism during the last 6 months

          -  Surgical procedures or acute illness during the last 30 days

          -  Chronic or acute infection

          -  Any other circumstance that may hamper patient prognosis for the next 6 months

          -  Serum creatine over 3.0mg/dL

          -  Serum potassium over 5.5 mEqs/L

          -  Any specific condition associated to the acute episode of decompensation, such as new
             onset cardiac arrhythmias, heart ischemia, infection, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edimar A Bocchi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Failure (InCor) University of São Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Institute of São Paulo University Medical School</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Rocha-e-Silva M, Poli de Figueiredo LF. Small volume hypertonic resuscitation of circulatory shock. Clinics (Sao Paulo). 2005 Apr;60(2):159-72. Epub 2005 Apr 26. Review.</citation>
    <PMID>15880253</PMID>
  </reference>
  <reference>
    <citation>Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G, Argano C, Tuttolomondo A, Paterna S. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J. 2003 Mar;145(3):459-66.</citation>
    <PMID>12660669</PMID>
  </reference>
  <results_reference>
    <citation>Issa VS, Bacal F, Mangini S, Carneiro RM, Azevedo CH, Chizzola PR, Ferreira SM, Bocchi EA. Hypertonic saline solution for renal failure prevention in patients with decompensated heart failure. Arq Bras Cardiol. 2007 Oct;89(4):251-5. English, Portuguese.</citation>
    <PMID>17992382</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Edimar Alcides Bocchi</investigator_full_name>
    <investigator_title>Heart Failure Team Director</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Renal failure</keyword>
  <keyword>Hyponatremia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hyponatremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

